APSR2026-973

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP11-024
P66
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1243270-46904-APSR2026-973_433827.pdf
Format: PDF Only
09. Asthma
1

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

MUHAMMED ANAS AYOOB * ZAYED MILITARY HOSPITAL PULMONARY MEDICINE ABU DHABI United Arab Emirates
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
MUHAMMED ANAS
AYOOB
dranazm@gmail.com
+971547891323
41-50
United Arab Emirates
Original Research
Clinical Outcomes of Biologic Switching in Patients with Uncontrolled Severe Asthma: A Real-World Retrospective Study from a Tertiary Care Center in the UAE
Maximum 25 words
Abstract Content
Biologic therapies have transformed the management of severe asthma; however, a substantial proportion of patients remain uncontrolled despite initial biologic treatment. Real-world evidence on outcomes after biologic switching is limited, particularly in Middle Eastern populations. The present study evaluates clinical outcomes, switching patterns, and predictors of response following biologic switching in patients with uncontrolled severe asthma at a tertiary care centre in the United Arab Emirates (UAE).
This retrospective observational cohort study included adult patients with severe asthma who underwent biologic switching between January 2020 and December 2025 at Zayed Military Hospital, Abu Dhabi. Clinical, biomarker, and treatment data were extracted from electronic medical records. The primary outcome was the change in the annualised exacerbation rate following the switch. Secondary outcomes included changes in Asthma Control Test (ACT) score, forced expiratory volume in one second (FEV₁), inflammatory biomarkers, hospitalisations, and safety outcomes. Paired statistical analyses, Poisson regression, and subgroup analyses by switching pathway were conducted.
Of 114 patients receiving biologics, 28 underwent biologic switching. The primary reason for switching was lack of efficacy (85.7%). Exacerbation rates significantly decreased after switching, with a mean reduction of 1.32 exacerbations per year (p<0.001), and 25% of patients achieved complete exacerbation remission at 12 months. ACT scores improved significantly from 11.86 to 17.36 (p<0.001), while FEV₁ demonstrated a modest improvement (+0.125 L). Significant reductions in FeNO and eosinophil counts were also observed. The overall response rate was 85.7%. Switching to dupilumab resulted in the greatest reduction in exacerbations. Adverse events were infrequent, and treatment discontinuation was primarily due to persistent uncontrolled disease.
Biologic switching was associated with significant improvements in asthma control, exacerbation frequency, inflammatory biomarkers, and healthcare utilisation among patients with uncontrolled severe asthma. These findings support biologic switching as an effective real-world strategy for individuals with an inadequate response to initial biologic therapy.
 
 
 
 
 
Yes
Yes
https://storage.unitedwebnetwork.com/files/1285/1243270-37089-switchingpattern_399333.png
JPG or JPEG or PNG format ONLY
severe asthma, biologic switching, asthma control
maximum 3 keywords and no abbreviations, separated by commas
nil
311